Exploring Regulated Bioanalysis For Small Molecules Bioanalysis 2020
Exploring Regulated Bioanalysis For Small Molecules Bioanalysis 2020 reveals several interesting facts.
- Zhen Zhang, CDER Office of Generic Drugs, explains the
- Patrick Faustino, CDER Office of Pharmaceutical Quality (OPQ), provides context for
- Zhen Zhang, CDER Office of Generic Drugs, explains how to identify challenges in establishing bioequivalence (BE) of drug ...
- Dr. Ryan Chu, the Director of Chemistry at Emery Pharma, will be presenting a series of talks covering various aspects of ...
- This is the first in a 3-Part Series of "The Weekly
In-Depth Information on Regulated Bioanalysis For Small Molecules Bioanalysis 2020
Diaa Shakleya, CDER Office of Pharmaceutical Quality (OPQ), discusses Jinhui Zhang, CDER Office of Pharmaceutical Quality, discusses the Biologics Price Competition and Innovation Act (BPCI) Act ... Salaheldin S. Hamed, CDER Office of Clinical Pharmacology, provides an introduction to biosimilars to include submission ... Director of the Office of Translational Sciences (OTS) ShaAvhrée Buckman-Garner, MD, PhD, FAAP, opened the meeting ...
Zhen Zhang and Tian Ma from the CDER Office of Generic Drugs respond to audience questions. FDA CDER's
Stay tuned for more updates related to Regulated Bioanalysis For Small Molecules Bioanalysis 2020.
